P3 Health Partners Inc. Form 8-K Summary
Business Context and Reporting Period
P3 Health Partners Inc. filed a Current Report on Form 8-K dated December 21, 2021, reporting a Nasdaq listing compliance development. The filing was signed on December 23, 2021.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
Nasdaq informed the Company that it had regained compliance with Nasdaq Listing Rule IM-5101-2 and the requirements of the Nasdaq Capital Market.
- The previously scheduled Nasdaq Hearings Panel hearing for January 13, 2022 was cancelled.
- The Company’s Class A common stock continued to trade on Nasdaq under the symbol PIII.
- The Company’s warrants continued to trade under the symbol PIIIW.
Outlook, Risks, and Unusual Items
The prior compliance issue involved the Company’s failure to demonstrate that its Class A common stock met the minimum 300 round lot holder requirement under Nasdaq Listing Rule 5505(a)(3). The warrants also did not qualify for initial listing because the underlying Class A common stock did not qualify.
The filing states that the Company appealed Nasdaq’s determination and requested a hearing before the Panel before subsequently regaining compliance. No additional financial guidance or management outlook is provided.
Facts for Investors to Verify
- Confirm the effective status of P3 Health Partners’ Nasdaq listing and continued trading symbols PIII and PIIIW.
- Review the Company’s December 3, 2021 Form 8-K for details of the original Nasdaq deficiency.
- Verify whether any subsequent filings identify additional listing requirements, conditions, or compliance risks.